Autopsy report · NCT04663126

Feasibility of IV Tc-99m-tilmanocept for Imaging of M2-like TAMs in Metastatic Melanoma

“after inclusion of 5 patients, tracer had low uptake (kidney/liver)”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 2 years 5 months before it stopped.
• 5 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Early Phase 1

Sponsor

John O. Prior

Sponsor type

University, hospital or other

Conditions

Melanoma

Interventions

Tc-99m tilmanocept

Participants

5

Sites

1

Countries

Switzerland

Trials that died the same way

• Predictive Value of 18F-FAZA in Rectum Cancer
  “The logistics of this trial (incl. supply of tracer) in connection with the patients' treatment course caused the inclusion rate to be very slow.” (59% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.